Neuroblastoma is one of the few childhood cancers that carries a tumor-specific antigen in the form of a glycolipid antigen known as GD2. It has restricted expression in normal tissue, such as peripheral afferent nerves. Monoclonal antibodies targeting GD2 have been applied clinically to high-risk neuroblastoma with significant success. However, there are different anti-GD2 products and administration regimens. For example, anti-GD2 has been used in combination with chemotherapy during the induction phase or with retinoic acid during the maintenance stage. Regimens also vary in the choice of whether to add cytokines (i.e., IL-2, GMCSF, or both). Furthermore, the addition of an immune enhancer, such as β-glucan, or allogeneic natural killer ...
Anti-GD2 antibody is a proven therapy for GD2-postive neuroblastoma. Monoclonal antibodies against G...
Background: Anti-GD2 based immunotherapy has improved overall (OS) and event free survival (EFS) for...
Anti-disialoganglioside GD2 antibody ch14.18/CHO (dinutuximab beta, DB) improved the outcome of pati...
Neuroblastoma is one of the few childhood cancers that carries a tumor-specific antigen in the form ...
Neuroblastoma is a pediatric solid cancer of heterogeneous clinical behavior. The unique features of...
Neuroblastoma is the most frequent extracranial childhood tumour but effective treatment with curren...
AbstractGanglioside GD2 is highly expressed on neuroectoderm-derived tumors and sarcomas, including ...
Background Neuroblastoma is a rare malignant disease that primarily affects children. The tumours ma...
Neuroblastoma originates from the cells in the neural crest. High-risk neuroblastoma, patients have ...
Disease recurrence is frequent in high-risk neuroblastoma (NBL) patients even after multimodality ag...
Neuroblastoma is an aggressive solid tumor that develops from immature cells of the nervous system a...
Although dose intensification of chemotherapy has increased initial response rates in neuroblastoma ...
Background The ganglioside GD2 is an attractive target for immunotherapy of neuroectodermal tumors....
Wayne L Furman Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USA...
Immunotherapy holds great promise for the treatment of pediatric cancers. In neuroblastoma, the rece...
Anti-GD2 antibody is a proven therapy for GD2-postive neuroblastoma. Monoclonal antibodies against G...
Background: Anti-GD2 based immunotherapy has improved overall (OS) and event free survival (EFS) for...
Anti-disialoganglioside GD2 antibody ch14.18/CHO (dinutuximab beta, DB) improved the outcome of pati...
Neuroblastoma is one of the few childhood cancers that carries a tumor-specific antigen in the form ...
Neuroblastoma is a pediatric solid cancer of heterogeneous clinical behavior. The unique features of...
Neuroblastoma is the most frequent extracranial childhood tumour but effective treatment with curren...
AbstractGanglioside GD2 is highly expressed on neuroectoderm-derived tumors and sarcomas, including ...
Background Neuroblastoma is a rare malignant disease that primarily affects children. The tumours ma...
Neuroblastoma originates from the cells in the neural crest. High-risk neuroblastoma, patients have ...
Disease recurrence is frequent in high-risk neuroblastoma (NBL) patients even after multimodality ag...
Neuroblastoma is an aggressive solid tumor that develops from immature cells of the nervous system a...
Although dose intensification of chemotherapy has increased initial response rates in neuroblastoma ...
Background The ganglioside GD2 is an attractive target for immunotherapy of neuroectodermal tumors....
Wayne L Furman Department of Oncology, St. Jude Children’s Research Hospital, Memphis, TN, USA...
Immunotherapy holds great promise for the treatment of pediatric cancers. In neuroblastoma, the rece...
Anti-GD2 antibody is a proven therapy for GD2-postive neuroblastoma. Monoclonal antibodies against G...
Background: Anti-GD2 based immunotherapy has improved overall (OS) and event free survival (EFS) for...
Anti-disialoganglioside GD2 antibody ch14.18/CHO (dinutuximab beta, DB) improved the outcome of pati...